|
 |
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular & Cellular Proteomics 3:345-354, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.
Research
How Industry Is Approaching the Search for New Diagnostic Markers and Biomarkers*
,
From Roche Diagnostics GmbH, Centralized Diagnostics, Nonnenwald 2, D-82377 Penzberg, Germany; and ¶ Hoffmann-La Roche Ltd., Roche Center for Medical Genomics, CH-4070 Basel, Switzerland
In the diagnostic and the pharmaceutical industry there is a constant need for new diagnostic markers and biomarkers with improved sensitivity and specificity. During the last 5 years, only a few novel diagnostic markers have been introduced into the market. Proteomics technologies are now offering unique chances to identify new candidate markers. Before a marker can be introduced into the market, three successive developmental phases have to be completed: the discovery phase, in which a variety of proteomics technologies are applied to identify marker candidates; the prototype developmental phase, in which immunological assays are established and validated in defined sample collectives; and finally the product development phase, with assay formats suitable for automated platforms. The hurdles that a potential candidate marker has to pass in each developmental phase before reaching the market are considerable. The costs are increasing from phase to phase, and in industry a number of questions concerning the medical need and the potential return on investment have to be answered before a proteomics discovery project is started. In this review, we will cover aspects of all three developmental phases including the repertoire of discovery tools for protein separation as well as giving an outline of modern principles of mass spectrometry for the identification of proteins.
To whom correspondence should be addressed: Roche Diagnostics GmbH, Nonnenwald 2, D-82377 Penzberg, Germany. Tel.: 0049- 8856-60-4145; E-mail: werner.zolg{at}roche.com
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Fu, J. Zhu, and J. E. Van Eyk Comparison of Multiplex Immunoassay Platforms Clin. Chem., February 1, 2010; 56(2): 314 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zolg The Proteomic Search for Diagnostic Biomarkers: Lost in Translation? Mol. Cell. Proteomics, October 1, 2006; 5(10): 1720 - 1726. [Full Text] [PDF]
|
|
|
|
 |
|
 Y Xiang and T Kato Use of Proteomics in Analysis of Autoimmune Diseases Lupus, July 1, 2006; 15(7): 431 - 435. [Abstract] [PDF]
|
|
|
|
 |
|
 R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Romeo, J. Wunderlich, L. Ngo, S. A. Rosenberg, S. M. Steinberg, and D. M. Berman Measuring Tissue-Based Biomarkers by Immunochromatography Coupled with Reverse-Phase Lysate Microarray Clin. Cancer Res., April 15, 2006; 12(8): 2463 - 2467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P S Tsai, J E Evans, K M Green, R M Sullivan, D A Schaumberg, S M Richards, M R Dana, and D A Sullivan Proteomic analysis of human meibomian gland secretions. Br J Ophthalmol, March 1, 2006; 90(3): 372 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Anderson The Roles of Multiple Proteomic Platforms in a Pipeline for New Diagnostics Mol. Cell. Proteomics, October 1, 2005; 4(10): 1441 - 1444. [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Eichacker, B. Granvogl, O. Mirus, B. C. Muller, C. Miess, and E. Schleiff Hiding behind Hydrophobicity: TRANSMEMBRANE SEGMENTS IN MASS SPECTROMETRY J. Biol. Chem., December 3, 2004; 279(49): 50915 - 50922. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |